The Surfers convene to discuss “Advancing the Public Health Agenda for NASH,” a paper recently published in Nature Reviews Gastroenterology and Hepatology, with lead author Jeffrey Lazarus and co-author Jörn Schattenberg.
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation summarizes the status of four ongoing trials and addresses issues of disease naming and the value of incorporating MRE into trial designs.
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation addresses the general issue or cirrhosis and reviews the FALCON 2 trial and belapectin post hoc Phase 2 data analysis.
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation addresses the general issue or cirrhosis and reviews the REVERSE study.
Jörn Schattenberg and Mazen Noureddin join the Surfers to discuss five recently-reported or ongoing clinical trials in NASH cirrhosis.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2020 TLMdX, the AASLD annual liver meeting. This conversation focuses on issues that will increase the richness of our understanding of disease and predictions for TLM 2022 (Hopefully not Digital only!)
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation includes a guest from the audience and focuses on an array of less conventional and more futuristic issues.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses how to make NITs the “gold standard” of drug development instead of biopsy.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on, in the words of Stephen Harrison, “putting a big, fat dent in Fatty Liver disease.”
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week’s just-concluded the AASDL 2021 TLMdX annual liver meeting.
Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD
Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green. They discussed the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021. This included the advocates’ priorities (both those who spoke in the PFDD session and others like our panelists) for changes in regulatory policy and programs.
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021 and the advocates’ perspectives that individuals brought to the meeting.
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021 and some personal experiences that made PFDD such a priority.
Global Liver Institute Founder, President, and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell, and Roger Green to review the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021.
In the third conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss a range of issues in the latter days of the conference, all loosely related to NASH Patient Management.
In the second conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss the breadth of NASH Drug/Disease Management on the weekend agenda.
In the first conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to focus on some of the basic NASH Science presentations during the first two days of the meeting.
Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH’s coverage of the event. This virtual meeting runs from November 12-15 and is scheduled on East Coast time.
Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about the availability of subgroup analysis.
Alina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial Endpoints from non-invasive testing data. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.
Alina Allen and Ian Rowe discuss how Liver Stiffness Measurements (LSM) can improve individual patient treatment in pre-cirrhotic and compensated cirrhotic patients. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about the availability of subgroup analysis.
Alina Allen and Ian Rowe join the Surfers to discuss the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.
Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic’s recent Hepatology publication, “MRE for prediction of long term progression and outcome in chronic liver disease.
